Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Change in Accured Expenses (2016 - 2025)

Conmed (CNMD) has disclosed Change in Accured Expenses for 16 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 13.27% year-over-year to $5.9 million, compared with a TTM value of $14.9 million through Dec 2025, up 626.22%, and an annual FY2025 reading of $14.9 million, up 626.22% over the prior year.
  • Change in Accured Expenses was $5.9 million for Q4 2025 at Conmed, down from $13.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $16.5 million in Q3 2022 and bottomed at -$15.0 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $1.4 million, with a median of $3.9 million recorded in 2023.
  • Peak annual rise in Change in Accured Expenses hit 903.29% in 2021, while the deepest fall reached 715.96% in 2021.
  • Year by year, Change in Accured Expenses stood at -$4.0 million in 2021, then dropped by 11.12% to -$4.5 million in 2022, then soared by 299.73% to $9.0 million in 2023, then tumbled by 41.67% to $5.2 million in 2024, then increased by 13.27% to $5.9 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CNMD at $5.9 million in Q4 2025, $13.3 million in Q3 2025, and $3.9 million in Q2 2025.